SESSION TYPE: COPD Posters II
PRESENTED ON: Wednesday, October 24, 2012 at 01:30 PM - 01:30 PM
PURPOSE: Factors associated with the length of hospital stay in patients admitted for acute exacerbation of COPD (AECOPD) have not been thoroughly evaluated. The purpose of this study is to evaluate the association between clinical and functional parameters with duration of hospital stay of patients admitted due to an AECOPD.
METHODS: We studied prospectively 47 patients (31 men, 16 women), mean age 70.1(±7.25) years, mean FEV1% 49.9(±14.4),mean FEV1/FVC% 53.6(±13.1), admitted to hospital for AECOPD. Pulmonary function tests including body box evaluation of lung volumes, Borg dyspnea score at rest, Visual analogue scale dyspnea score, 6 minute walking test (6 MWT), Chronic Respiratory Questionnaire (CRQ) total and 4 domains scores, Charlson index for comorbidities, blood gases on admission, were all parameters evaluated within 72h of admission. Frequency of exacerbations, long term oxygen therapy (LTOT) prior to admission and duration of hospital stay were also recorded.
RESULTS: Mean duration of hospital stay was 7 days. Patients divided in 2 groups: [ group 1: duration of stay < 7 days (26 patients), group 2: duration of stay ≥ 7 days (21 patients)]. Patients in group 1 had higher FEV1% pred [43.7 (±15.4) vs 35.2 (±11.7), p=0.046] and PEF% pred [70 (53.5, 84.0) vs 37.0(29.0, 53.0) p=0.050], lower Borg dyspnea score [4.7 (±2.1) vs 6.6 (±2.0) p=0.005] and higher Total CRQ score [83.6 (±12.2) vs 75.4 (±13.1) p=0.033]. Multiple regression analysis showed that lower FEV1% pred (p=0.05) and higher Borg dyspnea score (p=0.012) were associated with increased duration of hospital stay.
CONCLUSIONS: Functional impairment and dyspnea in patients admitted for AECOPD have significant impact on the duration of their hospital recovery. Neither comorbidities, nor exacerbation frequency had any influence on the duration of hospital stay.
CLINICAL IMPLICATIONS: Treatment interventions should be focused on expiratory flow limitation improvement in acute exacerbated COPD patients.
DISCLOSURE: The following authors have nothing to disclose: Fotini Karakontaki, Filia Diamantea, Andriana Papaioannou, Stamatoula Tsikrika, Athina Christakakou, Sofia Pouriki, Napoleon Karagiannidis, Vlasis Polychronopoulos, Marios Panagiotou
No Product/Research Disclosure InformationSismanoglio General Hospital, Athens, Greece